Table 2:
Smoking, Cancer Characteristics, and Relapse Rates
| Author / Year | Cancer Type | n | Baseline cigarettes/day | % relapse | Quit rate assessment time point |
|---|---|---|---|---|---|
| Chen 2014 | Head & Neck | 49 | 20 | 53% (23/49) | end of RT |
| Cooley 2007 | NSCLC | 70 | 22.7 | 30% (21/70) | Average 2.5 years |
| Cooley 2009 | NSCLC | 21 | 17 | 52% (11/21) | 4 months |
| deBruin-Visser 2012 | Lung, Head & Neck, Breast, Sarcoma, GU, others | 58 | 20 | 17% (10/58) | 12 months |
| Farley 2016 | Lung cancer | 6 | NR | 50% (3/6) | 3 months |
| Gulmond 2014 | Breast, GU, GI, Gyn, Head & Neck | 55 | 16 | 49.1% (27/55) | 4 months |
| Humphris 2004 | Oral | 53 | 17 | 13% (7/53) | 15 months |
| Krebs 2019 | Lung, GI, others | 20 | NR | 70% (14/20) | 1 month |
| Maher 2003 | Lung, Head & Neck | 93 | 31.5 | 12% (12/93) | 3 months |
| Martinez 2018 | Lung, Head & Neck, AML, GU, Gyn, GI, Liver, Pancreas, others | 357 | 20.8 | 25% (91/357) | 2 months |
| Matulewicz 2021 | GU | 2664 | NR | Unable to assess | |
| Naresh 2020 | Head & Neck | 500 | NR | 15% (75/500) | 2 years |
| Ostroff 2013 | Thoracic, Head & Neck, Breast, GYN, GU, others | 83 | 19.5 | 30% (25/83) | 6 months |
| Ostroff 1995 | Head & Neck | 74 | 27.76 | 35% (26/74) | Mean: 217 days |
| Park 2020 | Breast, GI, GU, Gyn, Head & Neck, Lung, Lymphoma, Melanoma | 74 | 10 | 29.7% (22/74) | 6 months |
| Paul 2019 | GU, GI, Breast, Lung, Melanoma, Heme, Head & Neck | 91 | NR | 22% (20/91) | 3.5 years |
| SandersonCox 2002 | NSCLC | 20 | 20 | 10% (2/20) | Mean: 14.9 months |
| Schnoll 2003 | Head & Neck, Lung | 30 | NR | 23% (7/30) | 3 months |
| Schnoll 2002 | Head & Neck, Lung | 30 | NR | 23% (7/30) | 3 months |
| Sheikh 2021 | NSCLC | 157 | NR | 5.1% (8/157) | average 7 year |
| Simmons 2013 | Head & Neck, Thoracic | 52 | 24.1 | 13% (7/52) | 12 months |
| Simmons 2020 | Thoracic, Head & Neck, GI, Breast, GU, Gyn, Heme, Cutaneous, others | 182 | 21.6 | 33% (60/182) | 12 months |
| Smailey 2021 | Head & Neck SCC | 56 | 42 | 30% (17/56) | 12 months |
| Smith 2020 | Head & Neck SCC | 18 | 50 pack years | 48% (8/18) | 3 months |
| Smith 2021 | Head & Neck | 21 | 42 pack years | 57% (12/21) | 3 months |
| Tomek 2003 | Second Head & Neck tumor | 91 | NR | Unable to assess | 6 months |
| Vitzthum 2015 | Lung | 131 | NR | 22% (29/131) | End of therapy |
| Walker 2004 | NSCLC | 43 | NR | 44% (19/43) | Mean: 33 months |
| Walker 2006 | NSCLC | 93 | 24.6 | 57% (53/93) | 12 months |
RT=Radiation Therapy, NSCLC=non-small cell Lung Cancer, GU=Genitourinary, GI=Gastrointestinal, Gyn=Gynecological, AML=Acute Myeloid Leukemia, SCC=Squamous Cell Carcinoma